EGFR and non-small cell lung carcinoma: In this study, we examined previously untreated NSCLC patients considered clinically unsuitable for chemotherapy in two groups, confirmed and suspected EGFR mutant, to evaluate the efficacy and safety of afatinib in both groups and explore the impact of ctDNA analysis.